dabigatran has been researched along with lopinavir in 2 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (lopinavir) | Trials (lopinavir) | Recent Studies (post-2010) (lopinavir) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 2,383 | 499 | 1,358 |
| Protein | Taxonomy | dabigatran (IC50) | lopinavir (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.7 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.12 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.035 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.5114 | |
| Protease | Human immunodeficiency virus 1 | 0.025 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.6 | |
| Protease | Human immunodeficiency virus 1 | 0.0175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barco, S; Coppens, M; Middeldorp, S; Stroobants, AK; van de Kerkhof, D; van den Dool, EJ | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
2 other study(ies) available for dabigatran and lopinavir
| Article | Year |
|---|---|
Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lopinavir; Male; Middle Aged; Protease Inhibitors; Pyridines; Ritonavir; Treatment Outcome; Vitamin K | 2014 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |